Previous 10 | Next 10 |
On April 3rd, Recro Pharma (REPH) publicized its decision to cut operating expenses at its Acute Care Segment by reducing employee headcount by 50. This is in reaction to the company receiving its second CRL from the FDA concerning its IV Meloxicam candidate. This strategy intends to decre...
Gainers : Yangtze River Port and Logistics (NASDAQ: YRIV ) +48% . Recro Pharma (NASDAQ: REPH ) +28% . Shineco (NASDAQ: TYHT ) +27% . SG Blocks (NASDAQ: SGBX ) +18% . Tonix Pharmaceuticals Holding (NASDAQ: TNXP ) +18% . Amtech Systems (NASDAQ: ASYS ) +15% . Amyris (NASDAQ: AMRS ) +13...
Shineco (NASDAQ: TYHT ) +39% . More news on: Shineco, Inc., Recro Pharma, Inc., Tonix Pharmaceuticals Holding Corp., Stocks on the move, Read more ...
Taking action after the FDA rejected IV meloxicam a second time, Recro Pharma (NASDAQ: REPH ) has launched a cost-cutting initiative in its Acute Care business, including the termination of about 50 employees, that it believes will significantly lower operating expenses and cash consumptio...
Implements Plan to Reduce Acute Care Segment Staff CDMO Segment Continues Strong Performance; Company Increases Revenue, Operating Income and EBITDA, as Adjusted* Guidance for 2019 Expects to Become Cash Flow Breakeven During Q3; Cash Flow Positive Second Half of 2019 Plans to ...
Just like 2016, 2020 presidential candidates are likely to make healthcare costs a top priority. How to deal with rising costs remains to be seen, but the good news is technology is already helping in some key settings. Telehealth and remote patient monitoring have seen increased tra...
Proteostasis Therapeutics (NASDAQ: PTI ) -56% on disappointing data on CF candidates. More news on: Proteostasis Therapeutics, Inc., Recro Pharma, Inc., Motif Bio plc, Stocks on the move, Read more ...
MALVERN, Pa., March 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the appointment of Arnaud Ajdler to the Company’s Board of Dir...
Recro Pharma ( REPH +1.2% ) is set for a significant down move after receiving a Complete Response Letter (CRL) from the FDA regarding its marketing application for IV meloxicam, its second. More news on: Recro Pharma, Inc., Healthcare stocks news, Stocks on the move, Read more ......
MALVERN, Pa., March 22, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced it has received a second Complete Response Letter (CRL) from the ...
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...